Arbutus Biopharma Corporation Stock News

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine. Moderna lost a petition trying to

WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron

Pfizer-BioNTech get the go ahead ($1.95 billion contract with the US Government) based on 60 healthy adults receiving first try at formulating the vaccine.

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With no safety concerns in the Phase 1 trial, Moderna's COVID-19 vaccine candidate is advancing into late-stage studies.

Moderna has mixed luck with patent snub, but moves ahead with COVID-19 vaccine. Sorrento advances acquisition of SmartPharm.

An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop

What the decision handed down Thursday by the Patent Trial and Appeal Board could mean for Moderna (ticker: MRNA) isn’t yet clear, but the stock fell 9.5% on Thursday, and was down another 5% Friday

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session. Moderna Lose

Shares of Moderna Inc. were down 4.7% in premarket trading on Friday, the day after the U.S. Patent and Trademark Office ruled in favor of Arbutus Biopharma Corp. in a patent dispute between the com

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) * Abbott Laboratories (NYSE: ABT) * ABIOMED, Inc. (NASDAQ: ABMD) * Acceleron Pharma Inc (NASDAQ: XLRN) * Aerpio Pharmaceuticals Inc (NA

An administrative court run by the U.S. Patent and Trademark Office rejected arguments by Moderna that an Arbutus patent known as the '069 patent should be revoked because it described obvious concept

Moderna Inc (NASDAQ: MRNA) has lost the bid to invalidate a key patent related to the development of several of its next-generation vaccines, including one meant for coronavirus, to Arbutus Biopharma